Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yu-Hsin Lin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Beta
- -1.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 257.03
Financials
Net Income
$-28.41MEBITDA
$-34.91MFree Cash Flow
$0.00EPS (diluted)
$-0.71Shares Outstanding (diluted)
40.18M+360.0%Operating Expenses
$34.91MCash & Debt
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-77.61M | $-2.31 |
| 2024 | $0.00 | $-36.14M | $-1.18 |
| 2023 | $0.00 | $-31.63M | $-1.19 |
| 2022 | $0.00 | $-12.65M | $-0.63 |
| 2021 | $0.00 | $-9.67M | $-0.40 |
| 2020 | $0.00 | $-5.75M | $-0.62 |
Valuation
BLTEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-75.00%Social Signal Score
Mentions (19)
- Newsglobenewswire.com·5d ago·Negative
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Innovate Retina conference being held on October 8, 2026, in New Orleans, Louisiana, and at th…
View source ↗ - Newsglobenewswire.com·7d ago·Negative
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held…
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·26d ago·Negative
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross Belite Bio, Inc. Sponsored ADR (BLTE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, BLTE's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
Belite Bio On Track For A Potential Blockbuster Launch In 2027
View source ↗ - Newsglobenewswire.com·28d ago·Negative
…he Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour, and Welfare (MHLW) in Japan for…
View source ↗ - Newsbenzinga.com·31d ago·Neutral
Why Is Belite Bio Stock Soaring Friday? Belite Bio Inc. (NASDAQ:BLTE) drew a bullish initiation from Canaccord Genuity, which sees significant upside tied to the potential launch of its lead eye-disease drug, tinlarebant.
View source ↗ - News (RSS)seekingalpha·33d ago·Neutral
Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 - Slideshow
View source ↗ - Newsmarketbeat.com·33d ago·Negative
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date.
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript
View source ↗ - Newsglobenewswire.com·35d ago·Negative
Belite Bio to Participate in Four Upcoming Investor Conferences SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in four upcoming investor conferences. Details of the presentations are as follows:
View source ↗ - Newsglobenewswire.com·42d ago·Negative
Belite Bio to Host Virtual Commercial Day on September 2, 2026 SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 – 9:30 a.m. ET.
View source ↗ - Newsglobenewswire.com·46d ago·Negative
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28…
View source ↗ - News (RSS)seekingalpha·53d ago·Positive
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Negative
Belite Bio Q2 Earnings Call Highlights Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the application priority review. The agency set a Prescription Drug User Fee Act action date of Feb. 12, 2027.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2026, and provided a business update.
View source ↗ - Newszacks.com·55d ago·Neutral
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administr
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.79 per share
Typical surprise -6.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.70 vs $-0.73beat
- Wed, May 20$-0.34 vs $-0.60beat
- Mon, Mar 2$-0.38 vs $-0.56beat
- Mon, Nov 10$-0.65 vs $-0.53miss
- Mon, Aug 11$-0.50 vs $-0.47miss
- Tue, May 13$-0.45 vs $-0.36miss
Estimates and results for BLTE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BLTE officers and directors.
- Bought
- —
- Sold
- $36.0m
0 trades
100 trades
- Scholl Hendrik Petersold
- Scholl Hendrik Petersold
- Scholl Hendrik Petersold
- Scholl Hendrik Petersold
- Scholl Hendrik Petersold
- Scholl Hendrik Petersold
- Scholl Hendrik Petersold
- Scholl Hendrik Petersold
Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BLTE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.